Stockholm Environment Institute US Center

New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

Retrieved on: 
Wednesday, October 25, 2023
Seniors, Biotechnology, Pharmaceutical, Health, FDA, Infectious Diseases, Consumer, Clinical Trials, RSV, COPD, Headache, Ageing, Food, Respiratory syncytial virus vaccine, III, Conditional sentence, US Foods, Safety, Heart, Diabetes, Stockholm Environment Institute US Center, Infection, Pneumonia, Chronic kidney disease, CDC, Chronic liver disease, Risk, Asthma, ACIP, GSK plc, GSK, Hospital, Pain, Chronic obstructive pulmonary disease, Fatigue, Vaccine, Pharmaceutical industry, Adjuvant

The vaccine elicited an immune response in adults aged 50 to 59 at increased risk for RSV disease due to select underlying medical conditions that was non-inferior to that observed in adults aged 60 and above, meeting the trial’s primary co-endpoint.

Key Points: 
  • The vaccine elicited an immune response in adults aged 50 to 59 at increased risk for RSV disease due to select underlying medical conditions that was non-inferior to that observed in adults aged 60 and above, meeting the trial’s primary co-endpoint.
  • The co-primary endpoint was also met for the broader group of adults aged 50 to 59 also enrolled in the trial.
  • Tony Wood, Chief Scientific Officer, GSK, said: “This trial reinforces our confidence in our RSV vaccine’s ability to help protect adults aged 50 to 59 at increased risk for RSV-LRTD.
  • Immune response in participants aged 50 to 59 with pre-defined stable chronic diseases leading to an increased risk of RSV disease was assessed (n=570).

The MOG Project, Pediatric Neurologist Secure CDC Approval to Adopt ICD-10 Code for Rare Disease MOGAD

Retrieved on: 
Monday, October 2, 2023
Insurance, Optic neuritis, General assembly, Disease, United Nations, Glycoprotein, CHLA, Neuroimmunology, ICD, Lou Ruvo Center for Brain Health, Knowledge Organization (journal), United Nations General Assembly, Centers for Disease Control and Prevention, Research, Brain, Children's Hospital, Multiple sclerosis, CDC, MOGAD, MD, Patient, Physician, Children's Hospital Los Angeles, Immune system, Optic nerve, Stockholm Environment Institute US Center, Transverse myelitis, Diagnosis, Knowledge, Neuromyelitis optica spectrum disorder, Barrow Neurological Institute, International Classification of Diseases, Video game–related health problems, FDA, Acute disseminated encephalomyelitis, WHO, World Health Organization, Medical device

OLNEY, Md., Oct. 2, 2023 /PRNewswire-PRWeb/ -- The MOG Project, a nonprofit organization committed to supporting the research and treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) announced that its Executive Director Julia Lefelar, with support from The MOG Project Executive Board and Children's Hospital Los Angeles (CHLA) Pediatric Neurologist Jonathan Santoro, MD, secured approval to have the US Centers for Disease Control and Prevention (CDC) create an ICD-10 code for MOGAD. As of October 1, 2023, an official code for MOGAD is included in the 10th edition of the International Classification of Diseases (ICD) and Related Health Problems, which is relied upon by physicians and insurance providers to classify diagnoses and advise treatment.

Key Points: 
  • Without a CDC code, MOGAD patients had previously been grouped in with patients with similar diseases like neuromyelitis optica spectrum disorder, optic neuritis, acute disseminated encephalomyelitis, transverse myelitis and even multiple sclerosis.
  • "For the MOGAD community, this CDC code is more than a win for better health outcomes and fewer insurance delays, it gives our rare disease an identity and legitimizes it."
  • "The addition of a MOGAD specific ICD-10 code allows patients to better access the therapies that they need to treat their disease," said Santoro.
  • "Further, it allows for disease monitoring across the country, which will increase knowledge and research on this rare neuroimmunology disorder."

Resistance to antibiotics in northern Nigeria: what bacteria are prevalent, and which drugs work against them

Retrieved on: 
Sunday, September 17, 2023
Gaps, Infection, Multidrug-resistant bacteria, Tetracycline, Antimicrobial stewardship, Physician, Antimicrobial spectrum, Hospital, Centers for Disease Control and Prevention, Whole genome sequencing, Urinary tract infection, Aminoglycoside, Drug resistance, Death, Patient, Laboratory, Time, Blood, Gene, Stockholm Environment Institute US Center, Beta-lactam, Bacteria, Tigecycline, News, Fosfomycin, Family, Antibiotics, Food preservation, Pharmaceutical industry, Vaccine

Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.

Key Points: 
  • Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.
  • The continent has the highest global burden of antimicrobial-resistant infections, with 114.8 deaths per 100,000 people.
  • Physicians need laboratory data to choose the right antibiotic, at the right dose, for the right period of time.
  • This can lead to choosing ineffective antibiotics, which can lead to increases in resistant bacteria.
  • In other words, to develop a list of what bacteria are prevalent in the region and which drugs work against them.
  • To accomplish this, we recently conducted a study of multidrug-resistant bacteria obtained from patients in six hospitals in northern Nigeria.

Drug-resistant bacteria in Nigeria

    • We chose to analyse bacteria that are resistant to more than one drug because they are the biggest challenge when treating infections.
    • We found that about 85% of the bacteria isolated from infections were resistant to the most commonly used antibiotics.
    • The good news was that two antibiotics, tigecycline and fosfomycin, remained very active even against highly resistant strains of bacteria.

Genetic mechanisms

    • This was done to understand what made these organisms so resistant to antibiotics at the molecular level.
    • The data revealed an astonishingly high number of genetic mechanisms making the microorganisms resistant.
    • In some cases, the genetic information encoding resistance was capable of being shared among other microorganisms.

The need for antimicrobial stewardship

    • Some of the resistance genes were capable of moving from one microorganism to another (mobile resistance genes).
    • Antimicrobial stewardship based on laboratory data is effective especially if done locally, regionally and nationally.

Antimicrobial resistance is everyone’s concern

    • Read more:
      Antimicrobial resistance calls for brainpower of a space agency and campaigning zeal of an NGO

      Fourth, there are things that everyone can do to help bring antibiotic resistance under control.

    • For example, the US Centers for Disease Control and Prevention list five things that everyone should know about drug resistance and 10 activities to protect yourself and your family against resistance.
    • He is affiliated with the International Society for Antimicrobial Chemotherapy.

Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity

Retrieved on: 
Tuesday, August 29, 2023
Cloud, Intelligence, Centers for Disease Control and Prevention, LLM, DNA, Intellectual property, TPU, Partnership, DARPA, Intelligence Advanced Research Projects Activity, Therapy, Codebase, Global Initiative, SARS-CoV-2, Biogen, Enterprise search, Agriculture, Biotechnology, Synthetic media, COVID-19, Concentric objects, Google Cloud Platform, Public, Sumitomo Chemical, Research, Genomics, Synthetic biology, Government, CDC, Cloud computing, BigQuery, Protein, Moscone Center, Collection, Machine learning, Google Cloud, Engineering, Novo Nordisk, Tensor, Stockholm Environment Institute US Center, Foundry, Drug discovery, Biology, Merck, AI, Ecosystem, GISAID, NYSE, IARPA, Mobile phone, Satellite navigation device, Video game, Network equipment provider, Syngenta, Bayer, Ginkgo

Ginkgo intends to make Google Cloud its primary cloud services provider, significantly increasing its next-generation cloud computing resources, positioning Ginkgo and its customers well as the need for cloud computing expands.

Key Points: 
  • Ginkgo intends to make Google Cloud its primary cloud services provider, significantly increasing its next-generation cloud computing resources, positioning Ginkgo and its customers well as the need for cloud computing expands.
  • "We believe that by partnering with Google Cloud, Ginkgo can supercharge our mission to make biology easier to engineer," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
  • Ginkgo operates as a horizontal biological engineering and biosecurity platform, working to accelerate and de-risk scientific R&D projects for customers across industries.
  • Ginkgo and Google Cloud anticipate fueling a number of new Ginkgo offerings and initiatives through the collaboration, including:
    Large language models for biological engineering: Ginkgo plans to leverage Google Cloud's Vertex AI platform and Ginkgo's expansive Codebase to build and train novel foundation and task-specific models for core biological engineering challenges, supported by Google Cloud Consulting .

UN Global Compact launches Business Guidance for a Just Transition in Supply Chains

Retrieved on: 
Thursday, August 3, 2023
Heart, Climate, Employment, Introduction, Policy, Risk management, Just transition, Stockholm Environment Institute, Attention, United Nations Global Compact, Publication, Child, Stockholm Environment Institute US Center, Corporation, Renewable energy

This is not only crucial for a company’s own operations, but also for their supply chains.

Key Points: 
  • This is not only crucial for a company’s own operations, but also for their supply chains.
  • It offers five recommendations for businesses to improve the sustainability and resilience of their supply chains through a just transition.
  • The Think Lab on Just Transition aims to shape and define business and thought leadership on critical areas linked to just transition; address key business challenges; identify policy advocacy opportunities and good business practices; and scale-up learnings through the network of the UN Global Compact.
  • If you’ve missed the previous publications in this series on just transition, we invite you to download the Introduction to Just Transition, Just Transition for Climate Adaptation and Financing a Just Transition business briefs today.

Spectacular Labs Unveils Future of Food Safety Testing

Retrieved on: 
Wednesday, July 12, 2023
Retail, Health, Supply Chain Management, Restaurant, Bar, Transport, Other Science, Research, Other Retail, General Health, Supermarket, Specialty, Science, Logistics, Food, Beverage, Cloud, International Association for Food Protection, IAFP, University, Workflow, Berkeley, Farmer, Food safety, Campylobacter, International Association, Doctor of Philosophy, Laboratory, Annual general meeting, Stockholm Environment Institute US Center, Labs, Entrepreneurship, Salmonella, Corona Labs Inc., Escherichia coli, Pharmaceutical industry, Vaccine, Listeria

Food and beverage companies will be able to detect pathogens on-site easily, and testing laboratories will be able to scale operations cost-effectively.

Key Points: 
  • Food and beverage companies will be able to detect pathogens on-site easily, and testing laboratories will be able to scale operations cost-effectively.
  • Spectacular Labs was founded in 2020 by scientists out of the University of California, Berkeley, to create an innovative pathogen detection platform that reduces inefficiencies and modernizes current testing workflows.
  • Spectacular Labs was the first company to fully automate the foodborne pathogen testing workflow from enrichment to reporting.
  • "Spectacular Labs is poised to modernize the traditional food safety testing process with a complete pathogen detection platform that accelerates turnaround times, automates workflows, and eliminates costly supply chain bottlenecks,” said George Powlick, Partner at Astanor Ventures.

United States Tobacco Markets Report 2023: Demand for Premium Cigars Having a Positive Impact on the Near $100 Billion Industry

Retrieved on: 
Thursday, July 6, 2023
Smoker, Advertising, Employment, Travel, Smoking, Nicotine, Marketing, TB, Tobacco, Fatality, Tobacco industry, National Survey on Drug Use and Health, Centers for Disease Control and Prevention, Person, Attitude, Competition, Market, Death, State, Investment, Smokeless tobacco, Cigarette, Smoke, Stockholm Environment Institute US Center, Growth, Heated tobacco product, Ageing, Forecast, Legislation, Online shopping, Health

There are a number of elements that influence the tobacco market in the United States, including addiction, marketing and advertising, societal and economic concerns, and globalization.

Key Points: 
  • There are a number of elements that influence the tobacco market in the United States, including addiction, marketing and advertising, societal and economic concerns, and globalization.
  • The industry has also made significant investments in marketing and advertising to promote tobacco usage and smoking.
  • Due to growing consumer awareness of the negative effects of tobacco use, the demand for tobacco in the United States is predicted to be low.
  • Company Profiles: Detailed analysis of the major companies present in the United States tobacco market.

US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making

Retrieved on: 
Thursday, June 22, 2023
Research, Infectious Diseases, FDA, Seniors, Biotechnology, Health, Consumer, Pharmaceutical, Science, ACIP, GSK, The New England Journal of Medicine, US Foods, Respiratory syncytial virus vaccine, Diabetes, Vaccination, United States Department of Health and Human Services, Season, Chronic lung disease, DSM-IV codes, Multimedia, Morbidity and Mortality Weekly Report, CDC, Death, GSK plc, RSV, State, Patient, Risk, MMWR, Stockholm Environment Institute US Center, Kidney, Ageing, Disease, III, Food, Vaccine, Poultry farming

GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of AREXVY (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 and older using shared clinical decision making.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of AREXVY (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 and older using shared clinical decision making.
  • Shared clinical decision making empowers patients in consultation with their healthcare providers to determine whether RSV vaccination is appropriate for them.
  • These data will be submitted to the US Food and Drug Administration (FDA) for review.
  • The ACIP recommendations will be forwarded to the director of the CDC and the US Department of Health and Human Services for review and approval.

GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons

Retrieved on: 
Wednesday, June 21, 2023
Other Health, Research, General Health, Pharmaceutical, Consumer, Infectious Diseases, Clinical Trials, Science, Biotechnology, Seniors, FDA, Health, ACIP, GSK, US Foods, Public, Poisson, CI, Season, Arthralgia, CDC, RSV, Myalgia, Risk, Stockholm Environment Institute US Center, Headache, III, Food, Fatigue, Vaccine

The trial also evaluated efficacy following an annual revaccination schedule as a confirmatory secondary endpoint.

Key Points: 
  • The trial also evaluated efficacy following an annual revaccination schedule as a confirmatory secondary endpoint.
  • The clinical development program will continue to evaluate longer term follow up and the optimal timing for potential revaccination.
  • Tony Wood, Chief Scientific Officer, GSK, said: “Our goal is to provide a high level of protection for older adults most at risk from RSV.
  • These data will be submitted to the US Food and Drug Administration (FDA) and other regulators for review.

Marie Mazur Appointed Chair of PharmaJet Board of Directors

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Vaccine, GSK, Doctor of Pharmacy, Partnership, INSEAD, Multimedia, Centers for Disease Control and Prevention, Strategic Advisory Group of Experts, Organization, Global Health, Task force, State, Stockholm Environment Institute US Center, Regulatory affairs, Pharmaceutical industry, Pharmacy, University of Paris, Sanofi

PharmaJet ,® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery, today announced that Marie Mazur, PharmD, has been appointed Chair of the Board of Directors.

Key Points: 
  • PharmaJet ,® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery, today announced that Marie Mazur, PharmD, has been appointed Chair of the Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20230606005094/en/
    Dr. Marie Mazur, new PharmaJet Board Chair, is a global business executive with 30+ years of pharmaceutical and vaccine industry experience including Sanofi, 3M, GSK and CSL Seqirus.
  • (Photo: Business Wire)
    “I am thrilled that Marie is our new Chair.
  • “I also want to express my gratitude to Ron who has been a guiding force for our company for over eleven years.”
    “I am honored to serve as PharmaJet Board Chair,” said Marie Mazur.